Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.76%. A quarter ago, it was expected that this company would post a loss of $1.17 per share when it actually produced a loss of $1.03, delivering a surprise of 11.97%.Over the last four quarters, the company has ...

Arcus Biosciences (RCUS) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Hello, everyone, and welcome to Arcus Biosciences First Quarter twenty twenty five Earnings and Financial Results Call. My name is Lydia, and I'll be your operator today. After the prepared remarks, there'll be an opportunity to ask questions. I'll now hand you over to Pia Eaves, Vice President of Investor Relations to begin. Please go ahead. Speaker1 Good afternoon and thank you for joining us on today's conference call to dis ...

COMBINING TO CURE ® Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer. May 6, 2025 CORPORATE PRESENTATION Notice of Trademark: The Arcus name and logo are the property of Arcus. All other trademarks used herein are the property of their respective owners and are used for reference purposes only. Such use should not be construed as an endorsement of Arcus. Forward-Looking Statements/Safe Harbor Forward Looking Statements ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ Commission File Number: 001-38419 __________________ ...

Exhibit 99.1 Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update Casdatifan (HIF-2a inhibitor) Casdatifan Updates: • Data from the Phase 1/1b ARC-20 study cohort evaluating casdatifan plus cabozantinib in immunotherapy (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) will be presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting • Additional data from the ARC-20 cohorts evaluating casdatifan monothe ...

Arcus Biosciences (NYSE: RCUS ) has undergone a period of mixed developments since last year, and the stock has continued to decline into April 2025. While the company still has sufficient cash and a broad pipeline, the immediate road ahead couldAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in RCUS over the ne ...

Core Insights - Arcus Biosciences, Inc. reported a quarterly loss of $1.03 per share, which was better than the Zacks Consensus Estimate of a loss of $1.17, representing an earnings surprise of 11.97% [1] - The company generated revenues of $36 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 9.67% and showing an increase from $31 million in the same quarter last year [2] - Arcus Biosciences shares have declined approximately 31.8% year-to-date, contrasting with the S&P 500's gain of 1.7% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.09 on revenues of $37.52 million, while for the current fiscal year, the estimate is -$4.73 on revenues of $111.81 million [7] - The estimate revisions trend for Arcus Biosciences is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Arcus Biosciences belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - Total revenues for 2024 increased to $258 million, a 121% increase from $117 million in 2023, primarily driven by a $107 million revenue catch-up from the Gilead collaboration [386]. - License and development service revenue for 2024 was $222 million, reflecting a significant 178% increase from $80 million in 2023 [385]. - Total operating expenses for 2024 were $588 million, a 29% increase from $457 million in 2023 [441]. - Net loss for 2024 was $283 million, a slight improvement from a net loss of $307 million in 2023 [443]. - Revenue recognized under the Gilead Agreements for the year ended December 31, 2024, was $243 million, with $215 million recognized when services were performed [439]. - The company recognized a cumulative catch-up revenue of $107 million in 2024 due to a contract modification with Gilead, which reduced net loss per share by $1.19 [523]. - The company reported a basic and diluted net loss per share of $3.14 for 2024, improving from $4.15 in 2023 [441]. - Loss before income taxes for the year ended December 31, 2024, was $282 million, compared to $301 million in 2023 [553]. Cash and Investments - As of December 31, 2024, the company had $992 million in cash, cash equivalents, and marketable securities, which, along with recent equity financing, is expected to fund operations for the foreseeable future [372]. - Cash and cash equivalents at the end of 2024 were $150 million, up from $127 million at the end of 2023 [446]. - Marketable securities increased to $828 million in 2024, compared to $632 million in 2023, representing a 31% increase [446]. - Cash flow from operating activities for 2024 was a net outflow of $170 million, compared to a net outflow of $306 million in 2023 [451]. - Cash used in investing activities for 2024 was $78 million, mainly from net purchases of marketable securities, while cash provided in 2023 was $218 million from net proceeds of marketable securities [410]. - Cash used in financing activities for 2024 included net proceeds of $228 million from the issuance of common stock to Gilead under the Third Stock Purchase Agreement Amendment [412]. - The company had cash, cash equivalents, and marketable securities of $992 million as of December 31, 2024, compared to $866 million in 2023 [426]. Research and Development - The company has a robust portfolio of investigational products, with its most advanced molecule, an anti-TIGIT antibody, currently in multiple Phase 3 registrational studies targeting lung and GI cancers [356]. - The company expects substantial increases in R&D expenses as it advances joint development programs with Gilead and prepares for regulatory approvals [379]. - Research and development expenses rose to $448 million in 2024, a 32% increase from $340 million in 2023, driven by late-stage development program activities [390]. - R&D expenses include costs for clinical studies, with significant components being third-party service provider costs [468]. - The company recognizes revenue from research, collaboration, and license arrangements, with no product sales reported [461]. Collaborations and Agreements - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future, relying instead on collaboration and license agreements [373]. - Gilead made an upfront payment of $175 million upon closing the initial collaboration agreement in 2020, and a total payment of $725 million for three programs in 2022 [491]. - In 2024, Gilead purchased 15.2 million shares for total gross proceeds of $320 million, with $87 million allocated as deferred revenue [487]. - The company entered into multiple amendments to the Gilead Collaboration Agreement, enhancing strategic partnerships [483]. - The company is contractually obligated to make significant payments upon achieving various development, regulatory, and commercial milestones, which are contingent on uncertain future events [415]. - The company recognized $28 million, $33 million, and $33 million in other collaboration revenue for the years ended December 31, 2024, 2023, and 2022, respectively [542]. Expenses and Liabilities - General and administrative expenses increased to $120 million in 2024, a 3% rise from $117 million in 2023, attributed to the complexity of supporting an expanding clinical pipeline [392]. - Impairment charges for long-lived assets amounted to $20 million in 2024, compared to no impairment in the previous year [394]. - The company had outstanding debt with a carrying value of $48 million as of December 31, 2024, bearing interest at a rate equal to the greater of 10.45% or the prime rate plus 1.95% [427]. - The company recognized a total liability of $26 million related to obligations to AstraZeneca as of December 31, 2024 [514]. Market and Risk Factors - The company is exposed to foreign currency exchange rate risk, but a hypothetical 20% adverse movement would not result in a material impact on its financial position or income [428]. - The effective tax rate for 2024 was impacted by a change in valuation allowance, resulting in a rate of (28.1)% [554].

Financial Performance - Arcus reported revenues of $36 million for Q4 2024, up from $31 million in Q4 2023, with $28 million from license and development service revenues related to Gilead collaboration[13]. - Total revenues for Q4 2024 were $36 million, a 16% increase from $31 million in Q4 2023[24]. - License and development service revenue increased to $28 million in Q4 2024, up from $22 million in Q4 2023, representing a 27% growth[24]. - The net loss for Q4 2024 was $94 million, compared to a net loss of $81 million in Q4 2023, indicating a 16% increase in losses[24]. - The company reported a basic and diluted net loss per share of $1.03 for Q4 2024, compared to $1.08 for Q4 2023[24]. Research and Development - Research and Development (R&D) expenses increased to $111 million in Q4 2024 from $93 million in Q4 2023, driven by higher costs in early-stage R&D and increased headcount[13]. - Research and development expenses rose to $111 million in Q4 2024, compared to $93 million in Q4 2023, reflecting a 19% increase[24]. - The Phase 3 PEAK-1 trial for casdatifan is expected to initiate in Q2 2025, evaluating its combination with cabozantinib in ccRCC patients[5]. - Casdatifan demonstrated a median progression-free survival (PFS) of 9.7 months in the 50mg twice-daily monotherapy cohort[12]. - Two cohorts in the ARC-20 study exceeded a 30% confirmed overall response rate (ORR) in ccRCC patients, with disease control rates between 81% and 87%[6]. - Arcus initiated the PRISM-1 Phase 3 trial for quemliclustat in pancreatic cancer in Q4 2024, with the first patient dosed in Japan in February 2025[9]. - The company expects to present initial data from the ARC-20 cohort evaluating casdatifan plus cabozantinib in mid-2025[12]. - Arcus plans to meet with the FDA in H1 2025 to discuss next steps for the ARC-9 study evaluating etrumadenant plus zimberelimab in metastatic colorectal cancer[10]. Financial Position - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $992 million, an increase from $866 million at the end of 2023, primarily due to a $320 million cash infusion from Gilead[13]. - Cash, cash equivalents, and marketable securities totaled $992 million as of December 31, 2024, up from $866 million a year earlier, representing a 15% increase[26]. - Total assets increased to $1,150 million in 2024 from $1,095 million in 2023, a growth of 5%[26]. - Total liabilities rose to $665 million in 2024, compared to $633 million in 2023, marking a 5% increase[26]. - Total stockholders' equity increased to $485 million in 2024 from $462 million in 2023, a 5% growth[26]. - The company expects its cash and investments to be sufficient to fund operations through initial pivotal readouts for its investigational products[19]. General and Administrative Expenses - General and Administrative (G&A) expenses were $28 million in Q4 2024, slightly down from $29 million in Q4 2023[13].

Company Overview - Arcus Biosciences is an oncology biotech company with a focus on developing combination therapies that complement certain disease pathways [1] - The company's intellectual property (IP) has the potential to enhance treatment outcomes when used in combination with other drugs [1] Analyst Background - The author, Myriam Hernandez Alvarez, holds a Ph D in computer applications from the University of Alicante, Spain, and has professional collaborations with Edgar Torres H [1] - The author's analyses are conducted independently and adhere to Seeking Alpha's Shared Association Guidelines [1] Disclosure Information - The author has no stock, option, or derivative positions in any of the mentioned companies and no plans to initiate such positions within the next 72 hours [2] - The article expresses the author's own opinions and is not influenced by any compensation or business relationships with the mentioned companies [2]